Engage PharmaKonsult
Commercial Advisory
Senior commercial guidance for biotechnology leaders navigating critical decisions from development through launch and commercialization.
Biotech Commercial Strategy
Strategy & organizational build
First Commercial Launch
First-launch strategy & execution
Launch Readiness Assessment
Independent readiness & risk assessment
Commercial Leadership
Leadership, culture & organizational performance
Rare Disease Commercialization
Specialized neuro & rare disease strategy
Commercial Due Diligence
Commercial opportunity & risk evaluation
Why Joseph McCoy
- 30+ years of biopharma leadership spanning commercialization, organizational build-out, and growth
- CEO-level strategic perspective and executive presence, with the ability to engage boards, investors, partners, and senior stakeholders in high-level strategic conversations
- Built commercialization strategies for three emerging companies, including organizational design, launch planning, and market development
- Proven launch leadership, with multiple products achieving #1 market performance
- Deep rare disease and specialty neurology experience across complex, specialized markets.
- Experienced in building and leading high-performance organizations with a strong culture of accountability and execution
- Ten-time Pinnacle Club leader, demonstrating a sustained record of commercial performance
- Leadership experience across Pfizer, Lundbeck, SK Life Science, and Xeris, combining large-pharma discipline with emerging-company agility
- Former U.S. Navy Officer, bringing mission-focused leadership, decisiveness, and accountability
Where Biotechnology Leadership Engages PharmaKonsult
Senior commercial perspective on decisions that can shape an asset, its commercialization strategy and the company behind it.
Commercial Decisions from Discovery through Phase 3
Bring commercial perspective into development decisions early—before clinical, market and investment assumptions become difficult to change.
Commercialize, Partner or License?
Evaluate the commercial opportunity, organizational requirements, investment and risk behind one of biotechnology’s most consequential strategic decisions.
Regulatory Pathway & Commercial Impact
Consider how regulatory strategy, indication sequencing, evidence requirements and potential labeling decisions may affect market opportunity and commercialization.
Is Your Culture Ready for What Comes Next?
Growth, clinical milestones and commercialization change organizations. Assess whether leadership, culture and ways of working are prepared for the company’s next stage.
Practice Areas
Four areas of commercial leadership
PharmaKonsult partners with biotechnology CEOs and boards across the commercial decisions that define company value—from culture and leadership through launch, rare disease, and therapeutic specialization.
Strategic Drug Development & Commercialization Advisory
Strategic advisory across biotechnology drug development and commercialization—helping leadership make the decisions that increase regulatory success, adoption, partnerships and long-term value.
A commercial lens across the development continuum—indication priority, evidence, centers and investigators, partnering, and commercialization sequencing.
Learn More
Commercial Leadership, Culture & Organizational Performance
High-performing commercial organizations are built through exceptional leadership, disciplined execution, and a culture of trust and accountability.
We help biotechnology companies recruit and develop leaders, optimize commercial organizations, and build cultures that sustain long-term performance.
Learn More
Specialty Neurology
Commercial and development strategy across specialty neurology—from epilepsy and rare neurological disorders to broader CNS opportunities.
We help companies evaluate clinical evidence, market potential, competitive positioning, access, partnering and commercialization.
Learn More
Rare Disease Commercialization
Rare disease markets require a different commercial model.
We help biotechnology companies understand patient identification, Centers of Excellence, specialist networks, market access, patient services and the commercial infrastructure required to translate innovation into commercial success.
Learn More
Case Study
When Clinical Results Don't Drive Adoption
A new epilepsy therapy entered a crowded market with highly differentiated clinical results, including compelling seizure-freedom data. Yet adoption among some sophisticated epilepsy centers did not appear consistent with the strength of the clinical evidence. The important question wasn't whether the clinical data were strong—it was why strong clinical data weren't translating into expected market behavior.
